2025-12-12

Indoco Remedies Receives USFDA Compliance Report for Patalganga API Facility

by GOAI

Indoco Remedies has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located in Patalganga, Maharashtra. The EIR confirms that the site complies with USFDA regulations following a recent inspection conducted by the agency.

The inspection assessed the facility's adherence to Good Manufacturing Practices (GMP) and other regulatory standards required for API production. The issuance of the EIR indicates that the manufacturing site meets the necessary requirements for producing pharmaceutical ingredients intended for use in products distributed in the United States. This development highlights Indoco Remedies' ability to maintain compliance with international quality and safety standards at its Patalganga facility.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 12, 2025